Regeneron Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Phase 1 Study of VEGF Trap in Patients With Diabetic Macular Edema
- Conditions
- Diabetic Macular Edema
- Interventions
- Drug: VEGF Trap-Eye
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2011-06-10
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 5
- Registration Number
- NCT00320814
Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD
- Conditions
- Macular Degeneration
- Interventions
- Drug: VEGF Trap
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2015-03-18
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 51
- Registration Number
- NCT00320775
- Locations
- 🇺🇸
Retina Centers, PC, Tuscon, Arizona, United States
🇺🇸Loma Linda University Health Care, Loma Linda, California, United States
🇺🇸Johns Hopkins Hospital School of Medicine, Baltimore, Maryland, United States
Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
- Conditions
- Familial Cold Autoinflammatory Syndrome (FCAS)Familial Cold UrticariaMuckle-Wells Syndrome (MWS)Genetic Diseases, Inborn
- Interventions
- Drug: Placebo
- First Posted Date
- 2006-02-08
- Last Posted Date
- 2011-12-06
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 104
- Registration Number
- NCT00288704
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
- Conditions
- Cancer
- First Posted Date
- 2004-05-19
- Last Posted Date
- 2016-06-03
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 25
- Registration Number
- NCT00082823
- Locations
- 🇺🇸
Memorial Sloan - Kettering Cancer Center, New York, New York, United States
🇺🇸Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
- Conditions
- Cancer
- First Posted Date
- 2004-05-19
- Last Posted Date
- 2016-06-03
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 25
- Registration Number
- NCT00083213
- Locations
- 🇺🇸
Memorial Sloan - Kettering Cancer Center, New York, New York, United States
VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma
- Conditions
- LymphomaUnspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-06-03
- Lead Sponsor
- Regeneron Pharmaceuticals
- Registration Number
- NCT00045266
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma
- Conditions
- Unspecified Adult Solid Tumor, Protocol SpecificLymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-06-03
- Lead Sponsor
- Regeneron Pharmaceuticals
- Registration Number
- NCT00036946
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States